GE (NYSE: GE) Healthcare and Lantheus Holdings, Inc. (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (collectively “Lantheus”), have ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

GE Healthcare and Lantheus Announce Start of a Phase 3 Clinical Trial of Flurpiridaz, an Investigational Agent Being Evaluated for the Detection of Coronary Artery DiseaseJuly 31, 2018 8:00 AM